Secretoneurin plasma levels are decreased after catheter ablation for atrial fibrillation - patients with AF produce lower SN levels than healthy individuals: the SAFE registry

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00843989%3A_____%2F25%3AE0111982" target="_blank" >RIV/00843989:_____/25:E0111982 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/61988987:17110/25:A2603D44

Výsledek na webu

<a href="https://doi.org/10.3389/fcvm.2025.1664855" target="_blank" >https://doi.org/10.3389/fcvm.2025.1664855</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.3389/fcvm.2025.1664855" target="_blank" >10.3389/fcvm.2025.1664855</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Secretoneurin plasma levels are decreased after catheter ablation for atrial fibrillation - patients with AF produce lower SN levels than healthy individuals: the SAFE registry

Popis výsledku v původním jazyce

Background: Secretoneurin (SN) is a neuropeptide that counterbalances disorders of cell calcium cycling via calmodulin and thus may be involved in arrhythmogenesis. We aimed to associate plasma standard biomarkers and SN levels before, during, and after catheter ablation for atrial fibrillation (AF) with various clinical and paraclinical variables, foremost AF recurrence. Methods: We prospectively enrolled consecutive patients undergoing catheter ablation for AF in University Hospital Ostrava between March 2023 and January 2024. SN was analyzed from venous, left atrial, and coronary sinus blood with the ELISA method. Plasma SN levels were compared before, during, and after ablation and with those of healthy individuals, with nonparametric tests. ClinicalTrials.gov ID: NCT05794464. Results: A total of 137 patients (64% males, age 63 ± 11) and 34 healthy individuals (38% males, mean age 31 ± 7.1) were included in the analysis. Plasma SN levels were significantly lower after the catheter ablation as compared with SN levels before (34.0 ± 15.1 and 40.0 ± 17.3 pmol/L, p = 0.032). Healthy individuals produced higher plasma SN levels (50.7 ± 15.3 pmol/L) as compared with those in patients with AF both before and after catheter ablation (p = 0.0068, p < 0.001). Furthermore, lower postprocedural levels of SN were associated with AF recurrence (p = 0.035). The C-statistic for SN after the procedure to separate presence or absence of AF recurrence was 0.65 with bootstrap 95% CI 0.5–0.8. Of note, SN after the procedure correlated with plasma NT-proBNP levels (p < 0.001). PFA caused greater myocardial damage than did RFA (p < 0.001); inflammatory markers were increased post procedurally in both the RFA and the PFA group. Subclinical intravascular hemolysis occurred in the PFA group. Conclusion: Plasma secretoneurin levels are decreased after catheter ablation for atrial fibrillation; patients with AF produce lower SN levels than healthy individuals. Lower postprocedural level...

Název v anglickém jazyce

Secretoneurin plasma levels are decreased after catheter ablation for atrial fibrillation - patients with AF produce lower SN levels than healthy individuals: the SAFE registry

Popis výsledku anglicky

Background: Secretoneurin (SN) is a neuropeptide that counterbalances disorders of cell calcium cycling via calmodulin and thus may be involved in arrhythmogenesis. We aimed to associate plasma standard biomarkers and SN levels before, during, and after catheter ablation for atrial fibrillation (AF) with various clinical and paraclinical variables, foremost AF recurrence. Methods: We prospectively enrolled consecutive patients undergoing catheter ablation for AF in University Hospital Ostrava between March 2023 and January 2024. SN was analyzed from venous, left atrial, and coronary sinus blood with the ELISA method. Plasma SN levels were compared before, during, and after ablation and with those of healthy individuals, with nonparametric tests. ClinicalTrials.gov ID: NCT05794464. Results: A total of 137 patients (64% males, age 63 ± 11) and 34 healthy individuals (38% males, mean age 31 ± 7.1) were included in the analysis. Plasma SN levels were significantly lower after the catheter ablation as compared with SN levels before (34.0 ± 15.1 and 40.0 ± 17.3 pmol/L, p = 0.032). Healthy individuals produced higher plasma SN levels (50.7 ± 15.3 pmol/L) as compared with those in patients with AF both before and after catheter ablation (p = 0.0068, p < 0.001). Furthermore, lower postprocedural levels of SN were associated with AF recurrence (p = 0.035). The C-statistic for SN after the procedure to separate presence or absence of AF recurrence was 0.65 with bootstrap 95% CI 0.5–0.8. Of note, SN after the procedure correlated with plasma NT-proBNP levels (p < 0.001). PFA caused greater myocardial damage than did RFA (p < 0.001); inflammatory markers were increased post procedurally in both the RFA and the PFA group. Subclinical intravascular hemolysis occurred in the PFA group. Conclusion: Plasma secretoneurin levels are decreased after catheter ablation for atrial fibrillation; patients with AF produce lower SN levels than healthy individuals. Lower postprocedural level...

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30201 - Cardiac and Cardiovascular systems

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2025

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Frontiers in cardiovascular medicine

ISSN

2297-055X

e-ISSN

2297-055X

Svazek periodika

12

Číslo periodika v rámci svazku

article 1664855

Stát vydavatele periodika

CH - Švýcarská konfederace

Počet stran výsledku

12

Strana od-do

1-12

Kód UT WoS článku

001605638200001

EID výsledku v databázi Scopus

2-s2.0-105020269769